Korro Bio Inc's Customers Performance

Name: Korro Bio Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

KRRO

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


KRRO's Source of Revenues		• List of KRRO Customers

for the same period Korro Bio Inc

• List of KRRO Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Korro Bio Inc's Comment on Sales, Marketing and Customers

News about Korro Bio Inc Contracts

Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110...

Breakthrough in Alpha-1 Antitrypsin Deficiency: Korro s KRRO-110 Receives Green Light for Clinical TrialsIn an exciting development for the treatment of Alpha-1 Antitrypsin Deficiency (AATD), Korro Bio has announced that it has received both Australian Human Research Ethics Committee (HREC) approval and Clinical Trial Notification (CTN) clearance to initiate its Phase 1/2a clinical study, dubbed REWRITE. This study marks a pivotal step for Korro, as it begins evaluating its pioneering therapeutic candidate, KRRO-110, which is designed to address the significant unmet medical needs of individuals suffering from this genetic disorder. Understanding Alpha-1 Antitrypsin DeficiencyAlpha-1 Antitrypsin Deficiency ...

Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference

A Promising Frontier: Preclinical Advances of KRRO-110 for Alpha-1 Antitrypsin Deficiency Korro Bio, Inc., a notable name in the burgeoning field of RNA editing technologies, has recently presented compelling preclinical data on its lead development candidate, KRRO-110, at the American Thoracic Society 2024 International Conference. This article will delve into the specifics of the new data, focusing on the efficacy, specificity, and potential of KRRO-110 to transform the therapeutic landscape for patients suffering from Alpha-1 Antitrypsin Deficiency (AATD). Alpha-1 Antitrypsin Deficiency (AATD) is a genetic disorder characterized by an inadequate amount of alpha-1 antitrypsin (AAT) in the bloodstream. Thi...

KRRO's Stock Performance relative to it's Customers

KRRO's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Korro Bio Inc	182.17	7.37	-106.64	58
SUBTOTAL	0.00	0.00	0.00	-

Sources: Korro Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Korro Bio Inc’s corporate clients.
For your research, we’ve provided 9 tables on Korro Bio Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.